

Clinical Policy: Opioid Use Disorder Treatments

Reference Number: PHW.PDL.145.01

Effective Date: 01/01/2020

Last Review Date: 11/2025

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness® that Opioid Use Disorder Treatments are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Opioid Use Disorder Treatments

A. Prescriptions That Require Prior Authorization

Prescriptions for Opioid Use Disorder Treatments that meet any of the following conditions must be prior authorized:

1. A non-preferred Opioid Use Disorder Treatment. See the Preferred Drug List (PDL) for the list of preferred Opioid Use Disorder Treatments at: <https://papdl.com/preferred-drug-list>.
2. An Opioid Use Disorder Treatment with a prescribed quantity that exceeds the quantity limit.

REMINDER: A prescription for a benzodiazepine, opioid analgesic, controlled substance sedative hypnotic, or carisoprodol requires prior authorization when a member has a concurrent prescription for a buprenorphine Opioid Use Disorder Treatment. Refer to the specific individual handbook chapters (e.g., Analgesics, Opioid Long-Acting, Analgesics, Opioid Short-Acting, Anticonvulsants, Anxiolytics, Skeletal Muscle Relaxants, Sedative Hypnotics) for corresponding prior authorization guidelines.

REMINDER: A prescription for an opioid analgesic requires prior authorization when a member has a concurrent prescription for Vivitrol.

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Opioid Use Disorder Treatment, the determination of whether the requested prescription is medically necessary will take into account whether the member:

1. Is prescribed the Opioid Use Disorder Treatment for treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration-approved package labeling OR a medically accepted indication; **AND**

2. For Lucemyra (lofexidine), is prescribed a dose and duration of therapy that are consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. For a non-preferred Opioid Use Disorder Treatment, **one** of the following:
 - a. For sublingual buprenorphine Opioid Use Disorder Treatment, has a history of therapeutic failure, contraindication, or intolerance of the preferred sublingual buprenorphine Opioid Use Disorder Treatments,
 - b. For an alpha-2 adrenergic agonist Opioid Use Disorder Treatment, has a history of therapeutic failure, contraindication, or intolerance of the preferred alpha-2 adrenergic agonist Opioid Use Disorder Treatments,
 - c. For a non-sublingual buprenorphine Opioid Use Disorder Treatment, has a history of therapeutic failure, contraindication, or intolerance of the preferred non-sublingual buprenorphine Opioid Use Disorder Treatments;

AND

4. If a prescription for an Opioid Use Disorder Treatment is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in PA.CP.PMN.59 Quantity Limit Override.

NOTE: If the member does not meet the clinical review guidelines and quantity limit guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Opioid Use Disorder Treatment. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the member.

D. Approval Duration:

Requests for prior authorization of Lucemyra (lofexidine) will be approved for a dose and duration of therapy consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature.

All other agents: 12 months

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020
Per direction from DHS, removing criteria for an oral buprenorphine Opioid Dependence Treatment when used in combination with a benzodiazepine or CNS depressant	01/13/2020
Q3 2020 annual review: no changes.	07/2020
Q1 2021: policy revised according to DHS revisions effective 01/05/2021	11/2020
Q1 2022: policy revised according to DHS revisions effective 01/03/2022	10/2021
Q1 2023 annual review: no changes.	11/2022
Q3 2023: policy revised according to DHS revisions effective 07/10/2023.	07/2023
Q1 2024 annual review: no changes.	11/2023
Q1 2024: policy revised according to DHS revisions effective 02/02/2024.	01/2024
Q1 2025 annual review: no changes.	11/2024
Q1 2026 annual review: no changes.	11/2025